CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Explore this paper's citation graph
Summary
Rituximab added to six cycles of CHOP is an effective treatment for young patients with good-prognosis diffuse large-B-cell lymphoma and the definition of two prognostic subgroups allows for a more refined therapeutic approach for these patients.
- Type
- article
- Published
- 2006-05-01
- Cited by
- 1,944
- References
- 17
- OpenAlex
- https://openalex.org/W2160305510
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4657814
Keywords
Medicine, Rituximab, CHOP, Internal medicine, Vincristine
References
- Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
- ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
- Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
- Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.
- World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.
- Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
- Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
- Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
- Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.
- Children with TEL/AML1-Positive Acute Lymphoblastic Leukemia (ALL) and Favorable Presenting Features May Benefit from the Use of Vincristine-Dexamethasone (VCR-DXM) Pulses on Top of Antimetabolite-Based Continuation Therapy.
- Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).
- Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
- Cord Blood-Derived T Cells Can Be Genetically Engineered to Be B-Lineage All-Specific: Towards Adoptive Immunotherapy after Umbilical Cord Blood Transplantation.
- Dose escalated CHOP + etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL
- A predictive model for aggressive non-Hodgkin's lymphoma.
Cited by
- Caracterización biológica y pronóstica del linfoma difuso de células grandes en la era de la inmunoquimioterapia
- What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma?
- Antibody therapy in aggressive lymphomas.
- Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus‐associated diffuse large B‐cell lymphoma: results of a phase II trial
- The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence
- Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
- Current treatment approaches for diffuse large B-cell lymphoma
- Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy
- Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
- Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
- Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin’s lymphoma
- Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
- Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
- High immunohistochemical expression of p‐AKT predicts inferior survival in patients with diffuse large B‐cell lymphoma treated with immunochemotherapy
- Successful treatment of primary malignant lymphoma of the penis by organ-preserving rituximab-containing chemotherapy
- Prevention of CNS relapse in diffuse large B-cell lymphoma.
- Characteristics and Prognosis of B-cell Lymphoma in HIV-infected Children in the HAART Era
- Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare
- Lenalidomide in Diffuse Large B-Cell Lymphoma
- Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma
Related papers
- Vincristine, prednisone, and daunomycin in acute leukemia of childhood. Writing committee
- Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune-mediated thrombocytopenia in dogs.
- Remission induction with L-asparaginase, vincristine, and prednisone in children with acute nonlymphoblastic leukemia.
- VM-26 with prednisone and vincristine for treatment of refractory acute lymphocytic leukemia.
- Vincristine and prednisone vs vincristine, L-asparaginase, and prednisone for second remission induction of acute lymphocytic leukemia in children.
- Remission maintenance in acute lymphocytic leukemia with hydroxyurea.
- L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia.
- Long‐term results of reinforcement therapy in children with acute leukemia
- Clinical and cytokinetic aspects of remission induction of childhood acute lymphoblastic leukemia (ALL): addition of an anthracycline to vincristine and prednisone.
- Combination chemotherapy for acute lymphocytic leukemia in adults: Results of a retrospective study in 82 patients